# US 5,705,161 A · Immunogenic meningococcal LPS and other membrane vesicles and vaccine therefrom > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,705,161 A - Document ID: US5705161A - Status: Granted - Kind: A - Application number: 08/411,727 - Filed: 1995-05-01 - Granted: 1998-01-06 - Earliest claimed: 1992-10-02 - Assignees: De Staat Der Nederlanden Vertegenwoordigd Door de Minister Van Welzijn, Volksgezondheid En Cultuur - Inventors: Peter Andre Van Der Ley; Jan Theunis Poolman; Peter Hoogerhout - Web page: https://patentgrep.com/patent/US5705161A ## CPC - C07K 14/22: from Neisseriaceae (F) - A61P 31/04: Antibacterial agents - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention is directed to an immunity providing B cell activating molecule derived from a meningococcal lipopolysaccharide (LPS) having at least one epitope, said molecule comprising at least the communal part of the oligosaccharide part (core region) of lipopolysaccharides specific for at least two meningococcal immunotypes, preferably immunotypes L2 and L3 and wherein in galactose is absent in the B cell activating part, as well as derivatives of the molecules with immuno reaction inducing capacity. The invention is also directed at an outer membrane vesicle provided with a group of polypeptides having at least the immunoactivity of outer membrane proteins (OMP's) bound to a membrane, a polypeptide from the group of said outer membrane vesicles being a membrane anchored OMP or OMP fragment with a mutation in one of the surface loops, preferably in a 2, 3, 5, 6, 7 or 8-loop of a class I OMP. Furthermore, the invention is directed at a vaccine comprising such an outer membrane vesicle and/or lipopolysaccharide, as well as methods for preparing a lipopolysaccharide and an outer membrane vesicle as described above. ## Claims ### Claim 1 A B cell activating molecule capable of providing immunity against meningococcal disease, said molecule being derived from a meningococcal, lipopolysaccharide (LPS) with at least one B cell activating epitope, said molecule comprising the lipid A part of the LPS and at least one communal part of the oligosaccharide part (core region) of lipopolysaccharides specific for at least two meningococcal immunotypes, wherein at least the terminal galactose residue of the lacto-N-neotetraose unit of the LPS is absent in the molecule. ### Claim 2 (depends on 1) Molecule according to claim 1, said molecule being derived from the L3 core and having the following structure: ##STR10## ### Claim 3 (depends on 1) Molecule according to claim 1, said molecule being derived from the L2 core and having the following structure: ##STR11## ### Claim 4 (depends on 1) A molecule according to claim 1, said molecule being derived from the L3 core and having the following structure ##STR12## ### Claim 5 (depends on 1) A molecule according to claim 1, said molecule being derived from the L2 core and having the following structure ##STR13## ### Claim 6 (depends on 1) A molecule according to claim 1, wherein the meningococcal immunotypes are L2 and L3. ### Claim 7 A B cell activating molecule capable of providing immunity against meningococcal disease, said molecule being derived from a meningococcal, lipopolysaccharide (LPS) with at least one B cell activating epitope, said molecule comprising the lipid A part of the LPS and at least one communal part of the oligosaccharide part (core region) of lipopolysaccharides specific for at least two meningococcal immunotypes, wherein at least one galactose residue of the lacto-N-neotetraose unit of the LPS is absent in the molecule, and wherein at least one glucose residue of said lacto-N-neotetraose unit of the LPS is retained in the molecule. ### Claim 8 (depends on 1) A method for preparing a molecule according to claim 1, wherein recombinant DNA techniques are used. ### Claim 9 (depends on 8) A method according to claim 8, wherein the molecule is obtained from a mutagenised production strain producing at least LPS without terminal galactose. ### Claim 10 (depends on 8) A method according to claim 8, wherein the molecule is obtained from a mutagenised production strain producing at least LPS without galactose. ### Claim 11 (depends on 8) A method according to claim 8, wherein the molecule is obtained from a mutagenised meningococcal production strain without galactose. ### Claim 12 (depends on 8) A method according to claim 8, wherein the molecule is obtained from a mutagenised production strain without galE. ### Claim 13 (depends on 8) A method according to claim 8, wherein the molecule is obtained from a mutagenised production strain without functional galE.